Lutetium Lu-177 JH020002 Injection

Lutetium-177 JH020002 · Bivision Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lutetium Lu-177 JH020002 Injection, covering 2025-05-13 to 2025-05-13. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer [Phase 1, Phase 2]

See pricing